One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.

But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.

How does the micro-cap biotech now finance a 700-patient phase 3 study?

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.